Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Ocular Therapeutix (NASDAQ: OCUL ) is a biotech working on treatments for retinal diseases. Since my June 2024 article on them, the company has focused on its flagship drug candidate called “Axpaxli.” For context, Axpaxli is intended for wet AMD asMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Busines ...